Active Ingredient(s):Zanubrutinib FDA Approved: * November 14, 2019 Pharm Company: *BEIGENE Category:Cancer
Zanubrutinib, sold under the brand name Brukinsa, is a medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), and marginal zone lymphoma (MZL). Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor. It is given by mouth.
It was approved for medical use in the United States in November 2019....
* May have multiple approval dates, manufacturers, or labelers.